Alexander Mackenzie - Pfizer President
| PFE Stock | MXN 432.30 0.64 0.15% |
President
Dr. Alexander R. Mackenzie is the Executive Vice President, Chief Development Officer of the company. He was Senior Vice President, Chief Development Officer from March 2016 until June 2016. Group Senior Vice President and Head, Pharma Therapeutics Research and Development from 2010 until March 2016. Senior Vice President, Head of Worldwide Research from 2007 until 2010. Dr. MacKenzie represents Pfizer as a member of the Board of Directors of ViiV Healthcare Limited. since 2016.
| Age | 58 |
| Tenure | 8 years |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1332 % which means that it generated a profit of $0.1332 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3687 %, meaning that it generated $0.3687 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Eric Harmon | DXC Technology | N/A | |
| Arthur Wong | DXC Technology | N/A | |
| Kleber Santos | Capital One Financial | 44 | |
| Malcolm Frank | Cognizant Technology Solutions | 51 | |
| Steven Schwartz | Cognizant Technology Solutions | 47 | |
| Matthew Farney | Genworth Financial | 46 | |
| Troy Richardson | DXC Technology | N/A | |
| Mahesh Shah | DXC Technology | N/A | |
| Michael Laming | Genworth Financial | 64 | |
| Yajnik Sanjiv | Capital One Financial | 60 | |
| Craig Stanley | McEwen Mining | 44 | |
| Kevin Jones | DXC Technology | N/A | |
| Gordon Coburn | Cognizant Technology Solutions | 51 | |
| Andrew Iaboni | McEwen Mining | 41 | |
| Srinivasan Veeraraghavachary | Cognizant Technology Solutions | 63 | |
| Robert Telesmanic | Cognizant Technology Solutions | 56 | |
| Allen Shaheen | Cognizant Technology Solutions | 55 | |
| Richard Corrado | Air Transport Services | 63 | |
| Michael Eberhardt | DXC Technology | N/A | |
| Pierre Bruno | DXC Technology | N/A | |
| Joseph Payne | Air Transport Services | 59 | |
Management Performance
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President of Global Established Pharma Bus. | ||
| Jennifer Damico, Controller VP | ||
| Frank DAmelio, CFO and Executive VP of Bus. Operations | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
| Helen Hobbs, Independent Director | ||
| Shantanu Narayen, Director | ||
| James Smith, Director | ||
| Christopher CFA, VP Officer | ||
| Dennis Ausiello, Independent Director | ||
| Mikael Dolsten, President - Worldwide Research and Development | ||
| Frances Fergusson, Independent Director | ||
| Stephen Sanger, Independent Director | ||
| Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
| Wyllie Cornwell, Independent Director | ||
| Suzanne Johnson, Independent Director | ||
| David Denton, Chief VP | ||
| Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
| DVM DVM, Chairman CEO | ||
| Geno Germano, Group President of Global Innovative Pharma Bus. | ||
| Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
| Sally Susman, Executive Vice President - Corporate Affairs | ||
| Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Freda LewisHall, Executive Vice President Chief Medical Officer | ||
| Rady Johnson, Executive Vice President Chief Compliance and Risk Officer | ||
| Mikael MD, Dev Research | ||
| Dan Littman, Director | ||
| Ian Read, Chairman, CEO and Chairman of Executive Committee | ||
| James Kilts, Independent Director | ||
| Don Cornwell, Independent Director | ||
| Charles Hill, Executive Vice President - Worldwide Human Resources | ||
| Joseph Echevarria, Director | ||
| Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
| Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Angela Hwang, Group President - Pfizer Essential Health | ||
| Scott Gottlieb, Director | ||
| Ronald Blaylock, Independent Director | ||
| Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
| Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.37 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 5.97 T | |||
| Shares Outstanding | 5.61 B | |||
| Shares Owned By Institutions | 70.47 % | |||
| Price To Earning | 27.15 X | |||
| Price To Book | 3.26 X | |||
| Price To Sales | 59.69 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |